Nina Weis

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie Razavi, Imam Waked, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2014 · 484 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +16

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Devin Razavi‐Shearer, Ivane Gamkrelidze, Calvin Q. Pan et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 404 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +13

Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes

Maria Pedersen, Helle Brüünsgaard, Nina Weis et al. · Mechanisms of Ageing and Development · 2003 · 347 citations

Medicine, Endocrinology, Geriatric Medicine +15

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Mark Sulkowski, Christophe Hézode, Jan Gerstoft et al. · The Lancet · 2014 · 280 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Strategies to manage hepatitis<scp>C</scp>virus (<scp>HCV</scp>) disease burden

Heiner Wedemeyer, A.‐S. Duberg, Marı́a Buti et al. · Journal of Viral Hepatitis · 2014 · 181 citations · Full text

Pharmacy, Infectious Disease Control, Infectious Diseases +13